Approximately half of the 60 SLC19A2 mutations associated with TRMA are missense variants (Supplemental Table 1) (5, 25), yet few have been functionally characterized. The gene discussed is SLC19A2; the disease is thiamine-responsive megaloblastic anemia syndrome.